1. Cardiovascular and cerebrovascular events among patients receiving omalizumab: Pooled analysis of patient-level data from 25 randomized, double-blind, placebo- controlled clinical trials 
Carlos Iribarren, MD, MPH, PhD, Kenneth J. Rothman, DrPH, Mary S. Bradley, MS, Gillis Carrigan, PhD, Mark D. Eisner, MD, Hubert Chen, MD, MPH 
Journal of Allergy and Clinical Immunology 
Volume 139, Issue 5, Pages (May 2017)
DOI: /j.jaci
Copyright © 2017 The Authors Terms and Conditions

2. Fig 1
Primary analysis: ATEs and other CV SAEs. Rate difference (A) and RR (B). CV, Cardiovascular; DVT, deep vein thrombosis; HTN, hypertension; MI, myocardial infarction; PE, pulmonary embolism; SAE, serious adverse event; TIA, transient ischemic attack.
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2017 The Authors Terms and Conditions

3. Fig E1
Journal of Allergy and Clinical Immunology  , DOI: ( /j.jaci )
Copyright © 2017 The Authors Terms and Conditions